Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other Non-Current Liabilities (2017 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Other Non-Current Liabilities for 10 consecutive years, with $141000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 96.32% to $141000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $141000.0 through Dec 2025, down 96.32% year-over-year, with the annual reading at $141000.0 for FY2025, 96.32% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $141000.0 at Cartesian Therapeutics, down from $848000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $45.5 million in Q1 2021, with the low at $141000.0 in Q4 2025.
  • Average Other Non-Current Liabilities over 5 years is $19.1 million, with a median of $18.0 million recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities surged 236.12% in 2023, then plummeted 96.32% in 2025.
  • Over 5 years, Other Non-Current Liabilities stood at $25.4 million in 2021, then decreased by 24.71% to $19.1 million in 2022, then crashed by 31.6% to $13.1 million in 2023, then tumbled by 70.7% to $3.8 million in 2024, then tumbled by 96.32% to $141000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $141000.0, $848000.0, and $3.8 million for Q4 2025, Q3 2025, and Q4 2024 respectively.